(NASDAQ: ALVO) Alvotech's forecast annual revenue growth rate of 27.74% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.66%, and it is also forecast to beat the US market's average forecast revenue growth rate of 11.9%.
Alvotech's revenue in 2025 is $562,478,000.On average, 3 Wall Street analysts forecast ALVO's revenue for 2025 to be $203,225,337,835, with the lowest ALVO revenue forecast at $196,477,926,447, and the highest ALVO revenue forecast at $215,331,977,472. On average, 2 Wall Street analysts forecast ALVO's revenue for 2026 to be $283,750,242,855, with the lowest ALVO revenue forecast at $266,450,146,785, and the highest ALVO revenue forecast at $301,050,338,926.
In 2027, ALVO is forecast to generate $365,582,626,318 in revenue, with the lowest revenue forecast at $327,080,876,128 and the highest revenue forecast at $404,084,376,507.